Russell Investments Group Ltd. decreased its holdings in Haemonetics Co. (NYSE:HAE) by 0.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 227,332 shares of the medical instruments supplier’s stock after selling 1,548 shares during the quarter. Russell Investments Group Ltd. owned 0.45% of Haemonetics worth $28,426,000 as of its most recent SEC filing.
A number of other institutional investors have also bought and sold shares of HAE. Eminence Capital LP grew its position in Haemonetics by 690.5% in the second quarter. Eminence Capital LP now owns 880,219 shares of the medical instruments supplier’s stock worth $105,926,000 after buying an additional 768,863 shares during the last quarter. Nuveen Asset Management LLC acquired a new position in Haemonetics in the second quarter worth approximately $50,613,000. Invesco Ltd. grew its position in Haemonetics by 700.8% in the second quarter. Invesco Ltd. now owns 435,592 shares of the medical instruments supplier’s stock worth $52,419,000 after buying an additional 381,196 shares during the last quarter. Wells Fargo & Company MN grew its position in Haemonetics by 17.3% in the second quarter. Wells Fargo & Company MN now owns 1,125,267 shares of the medical instruments supplier’s stock worth $135,416,000 after buying an additional 165,586 shares during the last quarter. Finally, Castleark Management LLC acquired a new position in Haemonetics in the second quarter worth approximately $13,808,000. Hedge funds and other institutional investors own 99.26% of the company’s stock.
Several research analysts have issued reports on HAE shares. Morgan Stanley lifted their price target on shares of Haemonetics from $128.00 to $148.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. ValuEngine upgraded shares of Haemonetics from a “hold” rating to a “buy” rating in a research report on Monday. Jefferies Financial Group lifted their price objective on shares of Haemonetics from $125.00 to $140.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. JMP Securities lifted their price objective on shares of Haemonetics to $145.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 7th. Finally, Raymond James lifted their price objective on shares of Haemonetics from $110.00 to $150.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 7th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $144.80.
In other Haemonetics news, CFO William P. Mr. Burke sold 7,164 shares of Haemonetics stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $125.80, for a total transaction of $901,231.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Christopher Simon sold 50,869 shares of Haemonetics stock in a transaction on Monday, August 19th. The shares were sold at an average price of $137.43, for a total transaction of $6,990,926.67. The disclosure for this sale can be found here. Insiders have sold a total of 103,735 shares of company stock valued at $13,462,081 in the last three months. Company insiders own 1.32% of the company’s stock.
NYSE HAE opened at $119.84 on Friday. Haemonetics Co. has a twelve month low of $80.24 and a twelve month high of $140.36. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.35 and a current ratio of 2.37. The stock has a market cap of $6.17 billion, a price-to-earnings ratio of 50.14, a PEG ratio of 2.84 and a beta of 0.77. The firm’s 50 day moving average price is $125.28 and its two-hundred day moving average price is $117.52.
Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.18. The firm had revenue of $238.50 million for the quarter, compared to analysts’ expectations of $236.82 million. Haemonetics had a net margin of 6.90% and a return on equity of 24.59%. The company’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.59 EPS. On average, research analysts forecast that Haemonetics Co. will post 3.18 EPS for the current fiscal year.
Haemonetics Company Profile
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Further Reading: What is a Futures Contract?
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.